Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Crinetics Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Crinetics Pharmaceuticals, Inc.

CRNX

Crinetics Pharmaceuticals, Inc.

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals is a clinical-stage biotech focused on developing oral, nonpeptide therapeutics targeting peptide GPCRs for endocrine diseases and tumors. Its pipeline includes treatments for acromegaly, carcinoid syndrome, and other hormonal disorders, emphasizing improved efficacy, safety, and patient convenience. The company leverages expertise in endocrine pathways, with proprietary molecules designed to address unmet medical needs in endocrinology and oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Crinetics Pharmaceuticals, Inc.

1
1
Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals Reports $10.7M Revenue in Q1 2026, Net Loss of $127.8M

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals Reports $7.7 Million Revenue and $465.3 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals Reports Q3 2025 Revenue Growth to $143,000 Amid Significant Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals Reports Q2 2025 Financial Results with Revenue Growth and Increased Losses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals Reports 44% Revenue Decline and Increased Losses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals Reports Significant Financial Developments, Decline in Revenue, and Increased Expenses in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments